Hsp90 and Grp94 Inhibitors for the Treatment of Primary Open Angle Glaucoma
- Technology Benefits
- Promising diagnostic toolMay provide new opportunities for the treatment of additional diseases
- Technology Application
- therapeutic strategy for myocilin glaucoma
- Detailed Technology Description
- Our inventors have developed a novel strategy that holds considerable promise for treating myocilin glaucoma. Through selectively targeting the endoplasmic reticulum chaperone Grp94 using siRNA knockdown or small molecule inhibitors, mutant myocilin can be removed in an efficient manner. Additionally, analogous inhibition of the paralog Hsp90 is under investigation as a therapeutic approach for a variety of diseases including cancer and Alzheimer's disease. The potential benefits of this treatment offers a significant effort towards understanding and preventing this disease.
- *Abstract
-
The University of South Florida has discovered selective heat shock protein 90 (Hsp90) and glucose regulated protein 94 (Grp94) inhibitors that can be used to develop an effective therapy for treating primary open angle glaucoma (POAG).
- Country/Region
- USA
For more information, please click Here
